ReviewFrontiers in oncology2026
The structure and functions of TRAF families and recent advances of TRAFs in leukemia.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia is a malignant clonal disease of hematopoietic stem cells. Currently, primary treatments include chemotherapy, targeted drugs, hematopoietic stem cell transplantation, and immunotherapy. Although advances in treatment have improved survival for leukemia patients, treatment failure still occurs in some individuals for various reasons. This necessitates the discovery of new pathogenic mechanisms and the exploration of novel biological targets. Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) are a family of cytoplasmic adapter proteins, typically comprising seven members. The TRAF protein family is widely involved in cell proliferation, differentiation, survival, and apoptosis, and also regulates immune and inflammatory responses. TRAFs perform dual roles in a broad range of biological activities-as adapter proteins and as E3 ubiquitin ligases-both essential for activating receptor-mediated signaling. In recent years, growing evidence has highlighted the significant role of TRAFs in leukemia, linking them to leukemic stem cell activity, drug resistance, apoptosis, and autophagy. This review introduces the functions and characteristics of TRAFs and summarizes research progress on their involvement in leukemia, underscoring their potential as novel therapeutic targets for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.